Glover Sarah, Nathaniel Rajkumar, Shakir Lubna, Perrault Cecile, Anderson Rebecca K, Tran-Son-Tay Roger, Benya Richard V
Dept. of Medicine, Univ. of Illinois at Chicago, 840 South Wood St., Chicago, IL 60612, USA.
Am J Physiol Gastrointest Liver Physiol. 2005 Jun;288(6):G1274-82. doi: 10.1152/ajpgi.00108.2004.
Gastrin-releasing peptide (GRP) is typically viewed as a growth factor in cancer. However, we have suggested that in colon cancer, GRP acts primarily as a morphogen when it and its receptor (GRP-R) are aberrantly upregulated. As such, GRP/GRP-R act(s) primarily to modulate processes contributing to the assumption or maintenance of tumor differentiation. One of the most important such processes is the ability of tumor cells to achieve directed motility in the context of tissue remodeling. Yet the cellular conditions affecting GRP/GRP-R expression, and the biochemical pathways involved in mediating its morphogenic properties, remain to be established. To study this, we evaluated the human colon cancer cell lines Caco-2 and HT-29 cells. We found that confluent cells do not express GRP/GRP-R. In contrast, disaggreation and plating at subconfluent densities results in rapid GRP/GRP-R upregulation followed by their progressive decrease as confluence is achieved. GRP/GRP-R coexpression correlated with that of focal adhesion kinase (FAK) phosphorylation of Tyr(397), Tyr(407), Tyr(861), and Tyr(925) but not Tyr(576) or Tyr(577). To more specifically evaluate the kinetics of GRP/GRP-R upregulation, we wounded confluent cell monolayers. At t = 0 h GRP/GRP-R were not expressed, yet cells immediately began migrating into the gap created by the wound. GRP/GRP-R were first detected at approximately 2 h, and maximal levels were observed at approximately 6 h postwounding. The GRP-specific antagonist [d-Phe(6)]-labeled bombesin methyl ester had no effect on cell motility before GRP-R expression. In contrast, this agent increasingly attenuated cell motility with increasing GRP-R expression such that from t = 6 h onward no further cell migration into the gap was observed. Overall, these findings indicate the existence of GRP-independent and -dependent phases of tumor cell remodeling with the latter mediating colon cancer cell motility during remodeling via FAK.
胃泌素释放肽(GRP)通常被视为癌症中的一种生长因子。然而,我们认为在结肠癌中,当GRP及其受体(GRP-R)异常上调时,GRP主要作为一种形态发生素发挥作用。因此,GRP/GRP-R主要作用是调节有助于肿瘤分化形成或维持的过程。其中最重要的过程之一是肿瘤细胞在组织重塑背景下实现定向运动的能力。然而,影响GRP/GRP-R表达的细胞条件以及介导其形态发生特性的生化途径仍有待确定。为了研究这一点,我们评估了人结肠癌细胞系Caco-2和HT-29细胞。我们发现汇合的细胞不表达GRP/GRP-R。相反,以亚汇合密度进行解离和平板接种会导致GRP/GRP-R迅速上调,随后随着汇合的实现其表达逐渐下降。GRP/GRP-R的共表达与粘着斑激酶(FAK)酪氨酸(Tyr)位点397、407、861和925的磷酸化相关,但与酪氨酸576或577的磷酸化无关。为了更具体地评估GRP/GRP-R上调的动力学,我们损伤了汇合的细胞单层。在t = 0小时时,GRP/GRP-R未表达,但细胞立即开始迁移到伤口形成的间隙中。GRP/GRP-R在大约2小时时首次被检测到,在伤口形成后约6小时观察到最高水平。GRP特异性拮抗剂[d-Phe(6)]标记的蛙皮素甲酯在GRP-R表达之前对细胞运动没有影响。相反,随着GRP-R表达的增加,该试剂对细胞运动的抑制作用越来越强,以至于从t = 6小时起,未观察到细胞进一步迁移到间隙中。总体而言,这些发现表明肿瘤细胞重塑存在GRP非依赖性和依赖性阶段,后者在重塑过程中通过FAK介导结肠癌细胞的运动。